Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, Drezner NL, Doebele RC, Blakely CM, Eberhardt WEE, Felip E, Gianni L, Keller SP, Leavey PJ, Malik S, Pignatti F, Prowell TM, Redman MW, Rizvi NA, Rosell R, Rusch V, de Ruysscher D, Schwartz LH, Sridhara R, Stahel RA, Swisher S, Taube JM, Travis WD, Keegan P, Wiens JR, Wistuba II, Wynes MW, Hirsch FR, Kris MG. Blumenthal GM, et al. Among authors: pignatti f. J Thorac Oncol. 2018 Dec;13(12):1818-1831. doi: 10.1016/j.jtho.2018.09.017. Epub 2018 Sep 27. J Thorac Oncol. 2018. PMID: 30268698 Free article. Review.
The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Boix-Perales H, Borregaard J, Jensen KB, Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D, Salmonson T, Bergh J, Schellens JH, Pignatti F. Boix-Perales H, et al. Among authors: pignatti f. Oncologist. 2014 Jul;19(7):766-73. doi: 10.1634/theoncologist.2013-0348. Epub 2014 Jun 13. Oncologist. 2014. PMID: 24928613 Free PMC article. Review.
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpier O, Bergh J, Karres D, Tzogani K, Gisselbrecht C, Pignatti F. Ali S, et al. Among authors: pignatti f. Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14. Oncologist. 2020. PMID: 32297447 Free PMC article.
The value of anticancer drugs - a regulatory view.
Pignatti F, Wilking U, Postmus D, Wilking N, Delgado J, Bergh J. Pignatti F, et al. Nat Rev Clin Oncol. 2022 Mar;19(3):207-215. doi: 10.1038/s41571-021-00584-z. Epub 2021 Dec 6. Nat Rev Clin Oncol. 2022. PMID: 34873312 Review.
The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M, Borregaard J, Ersbøll J, ten Bosch GJ, van Zwieten-Boot B, Abadie E, Schellens JH, Pignatti F. Nieto M, et al. Among authors: pignatti f. Clin Cancer Res. 2011 Nov 1;17(21):6608-14. doi: 10.1158/1078-0432.CCR-11-1734. Epub 2011 Oct 5. Clin Cancer Res. 2011. PMID: 21976546 Review.
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.
Pean E, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F. Pean E, et al. Among authors: pignatti f. Clin Cancer Res. 2012 Sep 1;18(17):4491-7. doi: 10.1158/1078-0432.CCR-11-3075. Epub 2012 Jul 24. Clin Cancer Res. 2012. PMID: 22829199
134 results